IPO

Senores Pharmaceuticals Limited IPO

Mainboard

Pharmaceuticals

Listed On: Dec 30, 2024 at ₹ 600.0(NSE)

₹ 14858 /38 Shares

Check Allotment

20 Dec, 2024

Open Date

24 Dec, 2024

Close Date

26 Dec, 2024

Allotment Date

30 Dec, 2024

Listing Date
Price Summary

Last Closing

771.00 (97.19%)

52 Week High

772.00

52 Week Low

435.25

Last Update

24-Oct-2025 3:30 PM
Senores Pharmaceuticals IPO Issue Details
  • Issue Price ₹372-391 per equity share
  • Face Value ₹10 Per Equity Share
  • Total Issue Size 1,48,87,723 shares(aggregating up to ₹582.11 crore)
  • Fresh Share 1,27,87,723 shares(aggregating up to ₹500 crore)
  • Offer For Sale 21,00,000 shares(aggregating up to ₹82.11 crore)
  • Listing at BSE, NSE
  • List Price 600.0(NSE)
  • Listing Date 2024-12-30
  • Lead Manager Equirus Capital Private Limited
    Ambit Private Limited
    Nuvama Wealth Management Limited
  • Registrar Link Intime India Private Ltd
Market Lot Size

Investors can bid for a minimum of 38 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

ApplicationLotsSharesAmount
Retail (min)138₹14,858
Retail(max)13494₹1,93,154
SHNI(min) 14532₹2,08,012
SHNI(max) 672,546₹9,95,486
BHNI(min) 682,584₹10,10,344
Senores Pharmaceuticals IPO Reservation

Senores Pharmaceuticals IPO offers total 1,48,12,723 shares. Out of which 44,43,817 (30%) allocated to QIB, 22,21,909 (15%) allocated to NII,14,81,272 (10%) allocated to RII, NA (NA%) allocated to employees and 66,65,725 (45%) allocated to Anchor investors.

Investor CategoryShares OfferedMaximum Allottees
Anchor Investor Shares Offered66,65,725 (45%)
QIB Shares Offered44,43,817 (30%)
NII (HNI) Shares Offered22,21,909 (15%)
bNII < ₹10L15,18,605 (10.25%)
sNII < ₹10L7,03,304 (4.75%)
Retail Shares Offered14,81,272 (10%)
Total Shares Offered1,48,12,723 (100%)
Senores Pharmaceuticals IPO Documents
DRHP
RHP
ANCHOR
Senores Pharmaceuticals IPO Details


Senores Pharmaceuticals IPO is a book-built issue of ₹582.11 crores, The total issue size is ₹582.11 crores. The IPO of Senores Pharmaceuticals is priced at ₹372-391 per equity share, which has a face value of ₹10 Per Equity Share each, IPO bidding starts from Dec 20, 2024 and ends on Dec 24, 2024. The allotment for Senores Pharmaceuticals IPO will be finalized on Dec 26, 2024. Senores Pharmaceuticals IPO will be listed on BSE, NSE, with a tentative listing date fixed as Dec 30, 2024. The company shall list its equity shares on the BSE, NSE. Link Intime India Private Ltd is the registrar of the issue.

Retail investors can bid for a minimum of 38 shares, extendable to 14,858. S-HNIs will be able to bid for 532 shares at ₹2,08,012, while B-HNIs can also apply for a bid of 2,584 shares at ₹10,10,344. The book-running lead manager for the IPO is/are Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited.

The total issue ₹582.11 crore, comprising a fresh issue of 1,27,87,723 shares ₹500 crore and having Offer for Sale (OFS) of 21,00,000 shares to mop up ₹82.11 crore.

The Senores Pharmaceuticals IPO sets its price band at 372-391 for each share. A single application for Senores Pharmaceuticals Limited IPO must contain at least 38 shares. Sentiment investors need to invest a minimum of 38 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,858 In order to participate in the sNII, investors must purchase at least 14 lots of 532 shares for ₹2,08,012, while the bNII requires 68 lots of 2,584 shares for an investment of ₹10,10,344.

Read More
Senores Pharmaceuticals IPO Subscription Analysis And Details
Retail
89.23x
QIB
94.66x
NII
96.11x
bNII
93.53x
sNII
101.27x
Total
93.41x
As onQIBNII
bNII   sNII		RetailTotal
Shares Offered / Reserved44,43,81722,21,909
15,18,605    7,03,304		14,81,27281,46,998
Day 1 20-12-24 05:00 PM
0.01 x1.67
1.11 x   2.80 x		7.20 x1.78 x
Day 2 23-12-24 05:00 PM
0.35 x24.48
20.14 x   33.15 x		38.32 x13.87 x
Day 3 24-12-24 05:00 PM
94.66 x96.11
93.53 x   101.27 x		89.23 x93.41 x
Total No of Applications
37,01,011
Subscription on the basis of Applications
Retail:77.82x BHNI:20.12x SHNI:106.99x
Senores Pharmaceuticals Valuations
EPS Pre IPO ₹9.83/-
EPS Post IPO ₹13.86/-
P/E Pre IPO 39.77
P/E Post IPO 28.21
ROE 23.60%
ROCE 11.73%
Debt/Equity 1.07
RoNW 23.60%
PAT Margin 15.25
Price to Book Value 5.84
Senores Pharmaceuticals Company Financials
In Crs.
In Cr.
31-Mar-2431-Mar-2331-Mar-22
Assets621.88131.0559.15
Revenue217.3439.0214.63
Profit After Tax32.718.430.99
Net Worth231.7145.536.59
Reserves & Surplus175.9435.2525.37
Total Borrowing248.3860.7614.21
About Senores Pharmaceuticals Company

Senores Pharmaceuticals is the world's leading research-driven pharmaceutical firm with a presence in several nations, engaged in the research and development, as well as manufacture of a myriad of pharmaceuticals products. The firm has thus built an independent niche in a regulated marketplace in US and Canada besides maintaining robust performance in emerging markets within 43 countries.

Senores Pharmaceuticals has strategically focused on specialty, underpenetrated, and complex pharmaceutical products and has emerged as the preferred partner for top-tier Indian and foreign pharmaceutical companies such as Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories, Sun Pharmaceuticals, Dr. Reddy's Laboratories Inc., and Cipla USA Inc.

The company has capabilities in a variety of therapeutic areas and multiple dosage forms, from the manufacturing of critical care injectables and APIs. Senores Pharmaceuticals possesses a fast-growing portfolio with 182 products registered as of March 31, 2024, and a further 245 filings ongoing.

Senores Pharmaceuticals with 113 employees operating by working lean yet efficiently keeps the innovation, regulatory compliance as well as quality manufacturing along with high-value pharmaceutical solutions delivering. Its commitment to research development and partnerships makes it very key in advancing healthcare solution across global markets.

This IPO is going to be an exciting stage for the company, aiming at the strengthening of its position in the market, product development, and exploitation of growing opportunities within the global pharmaceutical sector.

Read More
Senores Pharmaceuticals - Promoter(s)

Swapnil Jatinbhai Shah

Ashokkumar Vijaysinh Barot

Pre Issue Share Holding : 71.10%

Post Issue Share Holding : 45.77%

Senores Pharmaceuticals IPO - Issue Objectives
1

Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(Havix), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility

2

Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;

3

Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary

4

Funding the working capital requirements of the Company;

5

Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (SPI)and Ratnatris Pharmaceutical Private Limited (Ratnatris), to fund their working capital requirements.

6

Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Senores Pharmaceuticals IPO - Anchor Investors

Senores Pharmaceuticals IPO: Institutional investors invest Rs 261 crore via anchor book.

Domestic institutional investors like ICICI Prudential Mutual Fund, Aditya Birla Sun Life Insurance, Mahindra Manulife, Bank of India Mutual Fund, SBI General Insurance, Troo Capital, Meru Investment Fund and Edelweiss Life Insurance made investment in the company via anchor book.

Furthermore, Goldman Sachs, Societe Generale, Beacon Stone Capital, LC Pharos Multi Strategy Fund, Intergrated Global Strategies, and Fortune Hands Growth Fund also bought shares in the company via anchor book.

Senores Pharmaceuticals IPO - Peers Comparison
Company NameEPS (Basic)EPS (Diluted)NAV (per share) (Rs)P/E (x)RoNW (%)P/BV RatioFinancial statements
Ajanta Pharma Ltd.64.8264.77281.643.3423.477.96Consolidated
Alembic Ltd.31.3331.33245.1233.913.40.34Consolidated
Caplin Point Laboratories Ltd.60.7959.9309.0340.8421.694.26Consolidated
Gland Pharma Limited46.946.9529.6537.279.263.49Consolidated
Strides Pharma Science Ltd-7.76-7.76225.43N/A-4.445.64Consolidated

Notes:

  1. The P/E Ratio has been computed based on the closing market price of equity shares on December 13, 2024, divided by the Diluted EPS.
  2. Return on Net Worth (%) = Net profit after tax, as restated / Average shareholders' equity (including minority interest) as restated at year/period end.
  3. NAV is computed as the closing net worth (excluding minority interest) divided by the closing outstanding number of equity shares.
  4. Net worth means the aggregate value of the paid-up share capital of the Company and all reserves created out of profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation as at year/ period end, as per Restated Financial Statement of Assets and Liabilities of the Company.
Strength
Senores Pharmaceuticals has a US FDA-approved manufacturing facility in Atlanta, enhancing its ability to serve regulated markets.
The company’s Atlanta facility, approved by the DEA, can manufacture controlled substances, providing a competitive edge in the US market.
Senores Pharmaceuticals offers a one-stop CDMO solution, catering to pharmaceutical companies' development and manufacturing needs.
The company has built a strong product portfolio in emerging markets, focusing on complex products with less competition.
Weakness
The company’s reliance on third-party marketing partners and distributors exposes it to potential business disruptions if partnerships fail.
Strict adherence to quality standards is crucial for Senores Pharmaceuticals; any failure may lead to order cancellations and legal liabilities.
The company’s reliance on a few key customers makes it vulnerable to significant revenue loss if these customers terminate contracts.
Contact Details

Senores Pharmaceuticals

1101 to 1103, 11th floor,, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054

+91-79-29999857

cs@senorespharma.com

https://senorespharma.com/

Registrar Contact Details

Link Intime India Private Ltd

+91-22-4918 6270

senorespharma.ipo@linkintime.co.in

https://linkintime.co.in/initial_offer/public-issues.html